Barriers and facilitators to optimal oral anticoagulant management: a scoping review. 2020

Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada. wangm59@mcmaster.ca.

Oral anticoagulants (OACs) are high alert medications and require high-quality management to optimize health outcomes. The objective of this scoping review was to identify barriers and facilitators (B&Fs) associated with the quality of OAC management. We searched MEDLINE, EMBASE, and CINAHL databases until July 12, 2018, and cross-referenced the bibliographies of the retrieved studies. We included quantitative and qualitative studies that assessed B&Fs to OAC management. The study selection and data extraction processes were performed in duplicate. Analyses included measuring the prevalence of reported B&Fs from studies reporting quantitative data, identifying B&Fs in narrative analyses, and identifying their impact on important outcomes of OAC management. B&Fs were coded and aggregated to higher-level themes using a consensus approach. Factors were described as "key" if they were statistically associated with important outcomes in a randomized trial or observational study. We included 62 studies-three randomized clinical trials (RCTs), 46 observational studies (cross-sectional studies, cohort studies, and case-control studies), 11 qualitative studies, and two mixed-methods studies. Factors identified could be grouped into four themes-therapy-related, patient-related, healthcare provider-related, and health system-related. Key barriers to optimal OAC management were mostly patient-related, whereas interventions focused on education or implementing protocols were shown through RCTs to be effective at improving knowledge scores of OAC patients. While multiple barriers and some facilitators were identified in this review, none was proven to be associated with clinical outcomes. With this in mind, individual physicians may wish to address the key barriers in their practice as a quality improvement initiative but system-wide or policy changes should await high-quality evidence. Future trials should address these factors.Systematic review registration: PROSPERO CRD42017069043.

UI MeSH Term Description Entries
D011787 Quality of Health Care The levels of excellence which characterize the health service or health care provided based on accepted standards of quality. Pharmacy Audit,Quality of Care,Quality of Healthcare,Audit, Pharmacy,Care Quality,Health Care Quality,Healthcare Quality,Pharmacy Audits
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069552 Rivaroxaban A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide,BAY 59-7939,Xarelto,BAY 59 7939,BAY 597939
D000069604 Dabigatran A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. BIBR 1048,Dabigatran Etexilate,Dabigatran Etexilate Mesylate,N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine,Pradaxa,Etexilate Mesylate, Dabigatran,Etexilate, Dabigatran,Mesylate, Dabigatran Etexilate
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms
D014812 Vitamin K A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin
D019468 Disease Management A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596) Disease Managements,Management, Disease,Managements, Disease
D065427 Factor Xa Inhibitors Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor

Related Publications

Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2023, Journal of multidisciplinary healthcare,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2016, Nephrology nursing journal : journal of the American Nephrology Nurses' Association,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
March 2024, Journal of the International AIDS Society,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2024, SAGE open nursing,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
May 2023, Journal of thrombosis and thrombolysis,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
February 2021, Interactive journal of medical research,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2023, Heart & lung : the journal of critical care,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
October 2023, Journal of mental health (Abingdon, England),
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2018, BMC health services research,
Mei Wang, and Anne Holbrook, and Munil Lee, and Jiayu Liu, and Alvin Leenus, and Nora Chen, and Lawrence Mbuagbaw, and Lehana Thabane
January 2021, Systematic reviews,
Copied contents to your clipboard!